english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

• Decline in vigilance: water, water, everywhere...

Poisson d'avrilWater, water everywhere!  And not a drop of critical judgement. There's been a lot of water under the bridge since certain French researchers dove in at the deep end over just what water can and can't do. And now we have "highly rigorous researchers" and their findings on the properties of aqua naturalis. A reminder to always test the waters before you get your feet wet.
1 April 2019

Drugs to avoid in 2019

FEATURED REVIEW To make it easier to choose quality care, and to prevent disproportionate harms to patients, Prescrire has published its annual update of drugs to avoid. Using a reliable, rigorous and independent methodology, Prescrire's editors identified 93 drugs currently authorised in France or the European Union that are more harmful than beneficial in all the approved indications.
Full review (10 pages) available for free download.
1 April 2019

In the April issue of Prescrire International - Drugs in 2018: a brief overview

FREE DOWNLOAD In 2018, 99 new products or new indications were reviewed and rated in our French edition. Of the 35 that were deemed to advance patient care, 13 constituted a notable advance and 22 were rated "Possibly helpful", while 50 drugs were judged to be "nothing new".
Full text available for free download.
1 April 2019

Prescrire's ratings of new products and indications over the past 10 years

Each spring, Prescrire International publishes a recap of the drugs reviewed in our French edition during the previous year. It includes a table summing up the ratings Prescrire's editors gave to the new drugs and indications reviewed during each of the past ten years.
1 April 2019

Therapeutic advances in 2018 compared with the previous 10 years

Our recap of the drugs reviewed in our French edition La Revue Prescrire during the previous year includes a graphic summing up the ratings Prescrire's editors gave to new drugs and indications, compared with the previous ten years.
1 April 2019

Multiple sclerosis: wasted opportunities

The drugs on the market have been so poorly evaluated that healthcare professionals are not able to make the best use of the available treatments, to the detriment of patients.
1 April 2019

Pregnancy and lower urinary tract infection: opt for cefuroxime

Requiring just a single dose, fosfomycin trometamol is easier to take than cefuroxime or the combination of amoxicillin + clavulanic acid, but less is known about its short-term effects on the unborn child exposed during the first trimester of pregnancy. It is wiser to choose cefuroxime as first-line treatment.
1 April 2019

High-strength insulins: think and act in units of insulin to prevent errors

FEATURED REVIEW At home as in hospital (and other healthcare facilities), errors associated with insulin use are numerous, frequent and can have serious consequences. How can dosing errors due to the coexistence of different strengths of insulin on the market be prevented?
Full review (2 pages) available for download by subscribers.
1 March 2019

In the March issue of Prescrire International: Minor ischaemic stroke and antiplatelet drugs

FREE DOWNLOADIn this month's free sample text, the results of a trial confirming that after a minor stroke or transient ischaemic attack there is very little advantage from adding clopidogrel to aspirin, which remains the first-choice antithrombotic. 
Full text available for free download.
1 March 2019

Melatonin: significant adverse effects

Melatonin is not a treatment of choice for sleep disorders: its efficacy beyond that of a placebo is uncertain, and it carries a risk of neuropsychological, cutaneous, gastrointestinal and other adverse effects.
1 March 2019

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90